Year All202620252024202320222021202020192018201720162015201420122011 Aug 1, 2024 Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update Jul 31, 2024 Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion Jul 18, 2024 Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024 Jul 17, 2024 Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines Jul 2, 2024 To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA Jun 28, 2024 Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines May 30, 2024 Ardelyx, Inc. Reports Employment Inducement Grants May 22, 2024 Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference May 21, 2024 Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults May 16, 2024 Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)